Analyst Reco. Teva Pharmaceutical Industries Limited OTC Markets

Equities

TEVJF

IL0006290147

Market Closed - OTC Markets Other stock markets 02:02:46 2024-06-25 pm EDT			5-day change	1st Jan Change
14.7 ^USD	-18.33%		-18.33%	+70.53%

Jun. 28	Teva Pharmaceutical Industries Ltd Announces New AJOVY® (Fremanezumab) Migraine Prevention Data Challenges Treatment Pauses	CI
Jun. 27	Jefferies Adjusts Price Target on Teva Pharmaceutical Industries to $23 From $19, Maintains Buy Rating	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Jefferies Adjusts Price Target on Teva Pharmaceutical Industries to $23 From $19, Maintains Buy Rating	Jun. 27	MT
Teva Pharmaceutical Industries 'Well-Positioned' for Further Growth, UBS Says	Jun. 20	MT
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $21 From $20, Maintains Overweight Rating	Jun. 05	MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $470,794, According to a Recent SEC Filing	May. 17	MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $254,807, According to a Recent SEC Filing	May. 15	MT
Piper Sandler Adjusts Price Target on Teva Pharmaceutical Industries to $20 From $19, Maintains Overweight Rating	May. 13	MT
JPMorgan Upgrades Teva Pharmaceutical Industries to Neutral From Underweight, Adjusts Price Target to $14 From $11	Mar. 08	MT
Piper Sandler Upgrades Teva Pharmaceutical Industries to Overweight From Neutral, Adjusts PT to $19 From $12	Feb. 12	MT
Goldman Sachs Adjusts Price Target on Teva Pharmaceutical Industries to $11 From $10, Maintains Neutral Rating	Feb. 05	MT
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $17 From $15, Maintains Overweight Rating	Feb. 05	MT
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $15 From $14, Maintains Overweight Rating	Jan. 29	MT
Teva: share price up, broker in support	Jan. 23	CF
TEVA : Jefferies raises its recommendation	Jan. 23	CF
Jefferies Upgrades Teva Pharmaceutical Industries to Buy From Hold, Raises Price Target to $14 From $10	Jan. 23	MT
BofA Securities Adjusts Teva Pharmaceutical Industries Price Target to $14 From $13, Maintains Buy Rating	Jan. 12	MT
Piper Sandler Upgrades Teva Pharmaceutical Industries to Neutral From Underweight, Raises Price Target to $12 From $8	Jan. 03	MT
HSBC Initiates Teva Pharmaceutical Industries at Buy Rating With $13 Price Target	Dec. 18	MT
UBS Upgrades Teva Pharmaceutical Industries to Buy From Neutral, Adjusts Price Target to $13 From $11	Nov. 27	MT
UBS Upgrades Teva Pharmaceutical Industries to Neutral From Sell, Raises Price Target to $8 From $7	23-07-06	MT
Evercore ISI Upgrades Teva Pharmaceutical Industries to Outperform From In-Line	23-05-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Teva Pharmaceutical Industries isn't out of the woods yet

February 01, 2024 at 04:41 am EST

INTERVIEW - Richard Francis, CEO of Teva Pharmaceutical: solid quarter, full-year forecasts raised

August 02, 2023 at 03:19 pm EDT